Kelly Devine Deck B.S., CPA, M.S. Net Worth

Ms. Kelly Devine Deck B.S., CPA, M.S. biography

Kelly Devine Deck B.S., CPA, M.S. is the Chief Financial Officer at Inhibrx.

What is the salary of Ms S?

As the Chief Financial Officer of Inhibrx, the total compensation of Ms S at Inhibrx is $423,753. There are 3 executives at Inhibrx getting paid more, with Mark Paul Lappe having the highest compensation of $994,281.

How old is Ms S?

Ms S is 41, she's been the Chief Financial Officer of Inhibrx since . There are 4 older and no younger executives at Inhibrx. The oldest executive at Inhibrx, Inc. is Mark Paul Lappe, 54, who is the Founder, Chairman, Pres & CEO.

What's Ms S's mailing address?

Kelly's mailing address filed with the SEC is C/O INHIBRX, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.

Insiders trading at Inhibrx

Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol... oraz Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.

What does Inhibrx do?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Inhibrx executives and stock owners

Inhibrx executives and other stock owners filed with the SEC include:

• Mark Paul Lappe,
  Founder, Chairman, Pres & CEO
• Dr. Klaus W. Wagner,
  Chief Medical Officer & Exec. VP
• Dr. Brendan P. Eckelman Ph.D.,
  Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy
• Kelly Devine Deck B.S., CPA, M.S.,
  Chief Financial Officer
• Klaus Wagner,
  Executive Vice President, Chief Medical Officer
• Kelly Deck,
  Chief Financial Officer
• Quinn Deveraux,
  Co-Founder, Executive Vice President - Early Research
• Brendan Eckelman,
  Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer
• Mark Lappe,
  Chairman of the Board, Chief Executive Officer, Founder
• David Matly M.B.A.,
  Exec. VP & Chief Commercial Officer
• Jeffrey J. Jensen,
  Exec. VP of Clinical Operations
• Leah Pollema J.D.,
  VP, Corp. Sec. & Gen. Counsel
• Dr. Ashraf Amanullah,
  Exec. VP & Chief Technical Operations Officer
• Capital Management, L.P.Kol...,
  
• Brendan P. Eckelman,
  Chief Scientific Officer
• Jon Faiz Kayyem,
  Director
• Global Investors Lp Viking ...,
  
• Kristiina Md Vuori,
  Director
• Douglas Forsyth,
  Director
• Kimberly Manhard,
  Director
• Global Investors Lp Viking ...,
  
• Inc. Inhibrx,,
  
• Mark Lappe,
  Chief Executive Officer